Since understanding the role of individual CDK activities in specific tumour subtypes is essential to improve efficacy of CDK inhibitors in clinical practice, selective inhibition of CDK1 warrants further investigation as a potential therapy for MYC-dependent breast cancers. This evidence concerns the gene MYC and neoplasm.